Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Oxycephaly”

34 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 34 results

Early research (Phase 1)WithdrawnNCT04972253
What this trial is testing

Phase I BLASST-3 Trial

Who this might be right for
Bladder Transitional Cell CarcinomaBladder CancerFibroblast Growth Factor Receptor
Guru P. Sonpavde
Testing effectiveness (Phase 2)Study completedNCT04045613
What this trial is testing

Derazantinib and Atezolizumab in Patients With Urothelial Cancer

Who this might be right for
Urothelial Carcinoma
Basilea Pharmaceutica 95
Not applicableStudy completedNCT00340964
What this trial is testing

Positive Exposure: A Photography and Video Intervention for Individuals With Craniofacial Differences

Who this might be right for
Craniofacial Differences
National Human Genome Research Institute (NHGRI) 44
Early research (Phase 1)Active Not RecruitingNCT05567185
What this trial is testing

Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer

Who this might be right for
Urinary Bladder NeoplasmsReceptors, Fibroblast Growth Factor
Janssen Pharmaceutical K.K. 5
Testing effectiveness (Phase 2)Study completedNCT02924376
What this trial is testing

Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

Who this might be right for
Cholangiocarcinoma
Incyte Corporation 147
Testing effectiveness (Phase 2)WithdrawnNCT02747797
What this trial is testing

Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations

Who this might be right for
Advanced Cancer
Teresa Helsten, MD
Testing effectiveness (Phase 2)UnknownNCT05019794
What this trial is testing

Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations

Who this might be right for
Gastric CancerGastroesophageal Junction AdenocarcinomaSolid Tumor
LianBio LLC 80
Early research (Phase 1)Ended earlyNCT03144661
What this trial is testing

An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies

Who this might be right for
Hepatocellular Carcinoma (HCC)CholangiocarcinomaEsophageal Cancer+3 more
Incyte Corporation 25
Not applicableEnded earlyNCT00213889
What this trial is testing

TWIST Human Gene and Cleft Lips and Palates

Who this might be right for
Cleft Lip
University Hospital, Strasbourg, France 45
Testing effectiveness (Phase 2)Ended earlyNCT04003610
What this trial is testing

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Who this might be right for
Metastatic Urothelial CarcinomaUnresectable Urothelial Carcinoma
Incyte Corporation 7
Testing effectiveness (Phase 2)Study completedNCT02872714
What this trial is testing

Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)

Who this might be right for
UC (Urothelial Cancer)
Incyte Corporation 263
Testing effectiveness (Phase 2)Looking for participantsNCT07292168
What this trial is testing

A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1

Who this might be right for
Renal Cell Carcinoma MetastaticProstate Cancer MetastaticNon-small Cell Lung Cancer Metastatic+2 more
Kidney Cancer Research Bureau 58
Early research (Phase 1)Study completedNCT01703481
What this trial is testing

Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma

Who this might be right for
Tumor or Lymphoma
Janssen Research & Development, LLC 188
Not applicableNot Yet RecruitingNCT06322758
What this trial is testing

Driving Pressure-guided Tidal Volume Ventilation in the Acute Respiratory Distress Syndrome

Who this might be right for
Acute Respiratory Distress Syndrome ARDS
Assistance Publique - Hôpitaux de Paris 750
Early research (Phase 1)Study completedNCT03235570
What this trial is testing

A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)

Who this might be right for
Solid Tumors
Incyte Corporation 44
Testing effectiveness (Phase 2)Study completedNCT05253807
What this trial is testing

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Incyte Corporation 8
Testing effectiveness (Phase 2)WithdrawnNCT02846766
What this trial is testing

Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling

Who this might be right for
Cancer
Teresa Helsten, MD
Not applicableUnknownNCT01927354
What this trial is testing

Study on the Interplay Between Twist1 and Other EMT Regulators Through microRNA-29 Family.

Who this might be right for
Head-and-Neck Squamous Cell Carcinoma
National Taiwan University Hospital 100
Early research (Phase 1)Study completedNCT04572295
What this trial is testing

E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
Eisai Co., Ltd. 51
Early research (Phase 1)Active Not RecruitingNCT06160752
What this trial is testing

Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

Who this might be right for
Locally Advanced CholangiocarcinomaIntrahepatic CholangiocarcinomaSolid Tumor+1 more
Tyra Biosciences, Inc 40
Next Page